In The News Posted January 9, 2020 Share Posted January 9, 2020 BARCELONA, Spain and SUNNYVALE, Calif., Jan. 9, 2020 /PRNewswire/ -- Almirall, S.A. (ALM), a leading global pharmaceutical company focused on medical dermatology, and 23andMe, the leading consumer genetics and research company, have signed an agreement allowing Almirall to in-license... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.